IBC-Ab002, an anti-PD-L1 immunotherapy targeting systemic immune aging, is safe and reduces markers of neuronal damage in Alzheimer’s patients.
0%
IBC-Ab002, an anti-PD-L1 immunotherapy targeting systemic immune aging, is safe and reduces markers of neuronal damage in Alzheimer’s patients.
